HSP : Analysis & Opinions

  1. This $110 Billion Pharma Revolution Could Make Or Break Your ...

    February 19, 2015
    For sufferers of Rheumatoid Arthritis, Crohn's Disease, psoriasis, colitis and other auto-immune diseases, AbbVie, Inc.'s ...
  2. The Pharma Revolution That Could Rock Your Portfolio

    February 19, 2015
    For sufferers of Rheumatoid Arthritis, Crohn's Disease, psoriasis, colitis and other auto-immune diseases, AbbVie, Inc.'s ...
  3. Warning: 5 Popular Stocks You Need To Sell Now

    February 11, 2015
    These are five of the most widely owned stocks in the market. You have, without a doubt, heard of them, and it's very possible ...
  4. Warning: 5 Popular Stocks You Need to Consider Selling Now

    February 11, 2015
    These are five of the most widely owned stocks in the market. You have, without a doubt, heard of them, and it's very possible ...
  5. Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst ...

    January 21, 2015
    Hospira, Inc. (HSP) announced that it has received 510(k) regulatory clearance for the Plum 360 infusion system with Hospira ...
  6. Hospira Submits Retacrit Regulatory Application to the FDA - ...

    January 16, 2015
    Hospira, Inc. (HSP) announced that it has submitted a Biologics License Application looking to get Retacrit approved in the ...
  7. Hospira Inc. (HSP): New Analyst Report from Zacks Equity Research ...

    January 15, 2015
    Hospira's third-quarter 2014 adjusted earnings of $0.74 per share easily beat the Zacks Consensus Estimate of $0.53. Third-quarter ...
  8. Hospira's Dyloject Cleared in the U.S. for Pain Management - ...

    December 31, 2014
    The FDA has approved Hospira's (HSP) proprietary nonsteroidal anti-inflammatory drug analgesic, Dyloject.
  9. A Simple Way To Profit From The Fight Against Drug Abuse

    August 14, 2014
    From time to time we at StreetAuthority propose investments in "controversial" stocks that many of our readers ...
  10. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  11. In A Growth-Starved Sector, Becton Dickinson Rules

    May 3, 2013
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth. ...
  12. If CareFusion Can Execute, This Is A Major Bargain

    November 9, 2011
    CareFusion has to make some improvements, but it could really reward investors.
  13. Teva And Mylan Show Some Value Remains In Generics

    August 4, 2011
    These two generics companies seem to be heading in opposite directions, but the values are similar.
  14. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  15. Baxter A Healthy Healthcare Holding

    April 22, 2009
    Baxter's recent results demonstrate why it continues as a leader in its industry and should be considered a core healthcare ...
Trading Center